SkinPen® Precision Now Under Direct Management in the United Kingdom and Ireland

April 12, 2021 (Dallas, TX). Crown Aesthetics (“Crown”), a division of Crown Laboratories, Inc., is delighted to announce that SkinPen Precision, the first microneedling device cleared by the FDA and the gold standard for skin remodelling technology, now has a direct presence in the UK and Ireland.

The market arrival of Crown Aesthetics (formerly known as Bellus Medical) is a significant organizational investment that confirms Crown’s commitment to its customers and patients. Well-known for its dedication to excellence, Crown’s investment ensures a best-in-class level of service that SkinPen Precision customers and patients expect across the globe.

“By directly supporting our SkinPen customers, we will help them grow their practices by driving patient demand,” said Andy Moulton, Vice President of Sales, International for Crown Aesthetics. “They will now receive the superior level of training, education, and customer service they deserve.”

SkinPen Precision is a Class IIa medical device that works by creating controlled micro-injuries to stimulate the body’s natural wound-healing response and remodel scar tissue. Launched in 2013 and backed by over 90 validation studies*, SkinPen Precision is a superior US-engineered and manufactured skin remodelling device. SkinPen’s CE intended use includes treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appearance of fine lines and wrinkles on the face and neck. SkinPen also treats pigmentation conditions (Dyschromia) including Melasma, Vitiligo, and Solar Lentigines (sun/age spots). The award-winning SkinPen has a superior safety profile and is clinically proven effective on all Fitzpatrick skin types. Patients experience minimal cellular damage and little to no downtime.

SkinPen Precision websites: